Navigation Links
Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting
Date:12/3/2007

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that that it will hold an analyst and investor briefing in conjunction with The American Society of Hematology 48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10, 2007.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

Speakers:

-- Michael Morrissey, PhD, President of Research & Development of

Exelixis, Inc.

-- Gisela Schwab, MD, Senior Vice President & Chief Medical Officer of

Exelixis, Inc.

-- Ruben Mesa, MD of the Mayo Clinic

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 9, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode number is: 63491998.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
3. Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference
4. Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference
5. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... Momkus McCluskey Roberts LLC recently announced it was ... of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... matters of employment litigation, commercial litigation and business disputes. Her experience includes all aspects ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 ... ... list of the fastest growing companies in the U.S. for the second year in ... shown strong growth over the past three years. , “To be on the list ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & ... years in business this year, and they’re marking the milestone by undertaking a ... their patients. , It stands to reason that, given the central importance ...
(Date:8/16/2017)... ... 16, 2017 , ... The Southeastern Telehealth Resource Center at ... renewing its funding from the Health Resources and Services Administration (HRSA), part of ... fourth time the HRSA administration has renewed its financial support to GPT since ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: